PMID- 24138829
OWN - NLM
STAT- MEDLINE
DCOM- 20140707
LR  - 20131104
IS  - 1878-5905 (Electronic)
IS  - 0142-9612 (Linking)
VI  - 35
IP  - 1
DP  - 2014 Jan
TI  - An intravascular MRI contrast agent based on Gd(DO3A-Lys) for tumor angiography.
PG  - 327-36
LID - S0142-9612(13)01217-9 [pii]
LID - 10.1016/j.biomaterials.2013.10.006 [doi]
AB  - An intravascular MRI contrast agent Gd(DO3A-Lys), Gadolinium(III) 
      (2,2',2''-(10-(3-(5-benzamido-6-methoxy-6-oxohexylamino)-3-oxopropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate), 
      has been studied for tumor angiography based on its high relaxivity and long 
      blood half-life. The preparation procedures of the contrast agent have been 
      modified in order to achieve higher yield and improve the synthetic 
      reproducibility. High relaxivity of Gd(DO3A-Lys) has been confirmed by 
      measurements at 3 T, 7 T and 9.4 T magnetic fields. The relaxivity-dependent 
      albumin binding study indicated that Gd(DO3A-Lys) partially bound to albumin 
      protein. In vitro cell viability in HK2 cell indicated low cytotoxicity of 
      Gd(DO3A-Lys) up to 1.2 mM [Gd] concentration. In vivo toxicity studies 
      demonstrated no toxicity of Gd(DO3A-Lys) on kidney tissues up to 0.2 mM [Gd]. 
      While the toxicity on liver tissue was not observed at low dosage (1.0 mM [Gd]), 
      Gd(DO3A-Lys) cause certain damage on hepatic tissue at high dosage (2.0 mM [Gd]). 
      The DO3A-Lys has been labeled with (68)Ga radioisotope for biodistribution 
      studies. (68)Ga(DO3A-Lys) has high uptake in both HT1080 and U87MG xenograft 
      tumors, and has high accumulation in blood. Contrast-enhanced MR angiography 
      (CE-MRA) in mice bearing U87MG xenograft tumor demonstrated that Gd(DO3A-Lys) 
      could enhance vascular microenvironment around the tumor, and displays promising 
      characteristics of an MRI contrast agent for tumor angiography.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
FAU - Yang, Chang-Tong
AU  - Yang CT
AD  - Laboratory of Molecular Imaging, Singapore Bioimaging Consortium, Agency for 
      Science, Technology and Research (A*STAR), 11 Biopolis Way, #02-02 Helios, 
      Singapore 138667, Singapore. Electronic address: 
      yang_changtong@sbic.a-star.edu.sg.
FAU - Chandrasekharan, Prashant
AU  - Chandrasekharan P
FAU - He, Tao
AU  - He T
FAU - Poh, Zihan
AU  - Poh Z
FAU - Raju, Anandhkumar
AU  - Raju A
FAU - Chuang, Kai-Hsiang
AU  - Chuang KH
FAU - Robins, Edward G
AU  - Robins EG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131016
PL  - Netherlands
TA  - Biomaterials
JT  - Biomaterials
JID - 8100316
RN  - 0 (Contrast Media)
RN  - 0 (Heterocyclic Compounds)
RN  - 0 (Organometallic Compounds)
RN  - 0199MV609F (gadoteridol)
RN  - AU0V1LM3JT (Gadolinium)
RN  - K3Z4F929H6 (Lysine)
SB  - IM
MH  - Angiography/*methods
MH  - Animals
MH  - *Contrast Media
MH  - Female
MH  - Gadolinium/administration & dosage/chemistry/pharmacokinetics
MH  - Half-Life
MH  - Heterocyclic Compounds/*administration & dosage/chemistry/pharmacokinetics
MH  - Humans
MH  - Lysine/*chemistry
MH  - Magnetic Resonance Imaging/*methods
MH  - Mice
MH  - Mice, SCID
MH  - Neoplasms/*blood supply
MH  - Organometallic Compounds/*administration & dosage/chemistry/pharmacokinetics
MH  - Tissue Distribution
OTO - NOTNLM
OT  - Contrast agent
OT  - Gadolinium chelate
OT  - Magnetic resonance imaging (MRI)
OT  - Molecular imaging
OT  - Tumor angiography
EDAT- 2013/10/22 06:00
MHDA- 2014/07/08 06:00
CRDT- 2013/10/22 06:00
PHST- 2013/09/02 00:00 [received]
PHST- 2013/10/01 00:00 [accepted]
PHST- 2013/10/22 06:00 [entrez]
PHST- 2013/10/22 06:00 [pubmed]
PHST- 2014/07/08 06:00 [medline]
AID - S0142-9612(13)01217-9 [pii]
AID - 10.1016/j.biomaterials.2013.10.006 [doi]
PST - ppublish
SO  - Biomaterials. 2014 Jan;35(1):327-36. doi: 10.1016/j.biomaterials.2013.10.006. 
      Epub 2013 Oct 16.